Strattera Does Not Need to Be Tapered When Discontinuing at 40mg
Strattera (atomoxetine) can be discontinued abruptly at 40mg without tapering, as explicitly stated in the FDA prescribing information. 1
Direct FDA Guidance
The FDA-approved prescribing information clearly states: "STRATTERA can be discontinued without being tapered." 1 This applies to all doses, including 40mg, and represents the highest-quality evidence available for this specific medication.
Supporting Clinical Evidence
Multiple prospective studies confirm this guidance:
A large prospective, placebo-controlled study specifically assessed discontinuation effects after 9-10 weeks of continuous atomoxetine therapy in both children and adults with ADHD. The study found no statistically significant differences in discontinuation-emergent adverse events between patients who abruptly stopped atomoxetine versus those continuing on placebo. The authors concluded: "Tapering of doses is not necessary when atomoxetine is discontinued." 2
Additional research confirms that atomoxetine discontinuation is well tolerated with a low incidence of discontinuation-emergent adverse events, and patients may miss occasional doses without rebound effects or discontinuation syndrome 3, 4, 5
Clinical Context: Why Atomoxetine Is Different
Unlike medications that commonly require tapering (SSRIs, benzodiazepines, antipsychotics for tics, or lithium for mania), atomoxetine does not produce:
- Withdrawal symptoms requiring gradual dose reduction
- Symptom rebound to levels worse than baseline
- Discontinuation syndrome
While general pediatric psychopharmacology guidelines recommend tapering medications slowly to avoid withdrawal or rebound symptoms 6, these recommendations specifically cite examples like benzodiazepines, SSRIs, antipsychotics, and lithium—not atomoxetine.
Important Monitoring Considerations
Although tapering is not required, you should still:
- Monitor for return of ADHD symptoms over the following weeks, as symptoms may gradually worsen (though not rebound below baseline levels) 2
- Recognize that hyperactivity symptoms may return within hours to days, while inattentive symptoms may take longer to re-emerge 6
- Develop a monitoring plan before discontinuation to assess whether continued treatment is needed
Common Pitfall to Avoid
Do not confuse the gradual return of ADHD symptoms with a discontinuation syndrome. The prospective studies showed that while ADHD symptoms worsened after stopping atomoxetine, they did not return to pretreatment levels and this represents the natural course of untreated ADHD, not a withdrawal effect 2.